List of Excipients in Branded Drug EQUATE ESOMEPRAZOLE MAGNESIUM

« Back to Dashboard

Generic Drugs Containing EQUATE ESOMEPRAZOLE MAGNESIUM

Company	Ingredient	NDC	Excipient
Wal-Mart Stores Inc	esomeprazole	49035-921	FD&C BLUE NO. 1
Wal-Mart Stores Inc	esomeprazole	49035-921	FD&C RED NO. 3
Wal-Mart Stores Inc	esomeprazole	49035-921	FERRIC OXIDE RED
Wal-Mart Stores Inc	esomeprazole	49035-921	GELATIN
Wal-Mart Stores Inc	esomeprazole	49035-921	GLYCERYL MONOSTEARATE

What are the Most Frequently-Used Excipients in EQUATE ESOMEPRAZOLE MAGNESIUM?

# Of NDCs	Excipient
1	ACACIA
1	D&C YELLOW NO. 10
3	FD&C BLUE NO. 1
1	FD&C BLUE NO. 1 ALUMINUM LAKE
3	FD&C RED NO. 3

Equate Esomeprazole Magnesium Excipient Strategy and Commercial Opportunities

Last updated: August 3, 2026

Equate esomeprazole magnesium is an over-the-counter proton pump inhibitor positioned as a lower-price alternative to Nexium 24HR. Its commercial value depends less on active-ingredient exclusivity than on reliable enteric protection, low manufacturing cost, retailer control, and differentiated delivery formats. The strongest opportunities are formulation improvements that preserve acid stability, reduce tablet or capsule size, improve swallowability, and support private-label expansion.

What is Equate esomeprazole magnesium?

Equate esomeprazole magnesium is a store-brand formulation of esomeprazole magnesium, the magnesium salt of the S-enantiomer of omeprazole. The product is generally marketed as a 20 mg delayed-release oral dosage form for frequent heartburn, with a labeled regimen of one dose daily for up to 14 days.

Attribute	Commercial profile
Active ingredient	Esomeprazole magnesium
Therapeutic class	Proton pump inhibitor
Typical OTC strength	20 mg esomeprazole equivalent
Dosage form	Delayed-release tablet or capsule, depending on SKU and supplier
Primary indication	Frequent heartburn
Retail brand	Equate
Retailer	Walmart
Reference competition	Nexium 24HR
Regulatory pathway	OTC monograph-based proton pump inhibitor market
Primary commercial differentiator	Price, retailer distribution, and packaging
Biosimilar exposure	None

The exact inactive-ingredient profile can vary by Equate product code, dosage form, and contract manufacturer. A commercial excipient assessment should therefore be performed at the National Drug Code and current label level rather than at the Equate brand level.

What excipients are used in esomeprazole magnesium delayed-release products?

Esomeprazole is acid-labile. The dosage form must prevent release in the stomach and deliver the drug to the intestine. Excipients typically support four functions: core formation, drug stabilization, enteric protection, and film performance.

Core excipients

Common core excipients in esomeprazole delayed-release products include:

• Microcrystalline cellulose as a diluent and compression aid
• Mannitol or lactose as a soluble filler
• Crospovidone or croscarmellose sodium as a disintegrant
• Povidone or copovidone as a binder
• Magnesium stearate or sodium stearyl fumarate as a lubricant
• Colloidal silicon dioxide as a glidant
• Talc as an anti-adherent or coating aid

Capsule-based products may use drug-loaded pellets or multiparticulates rather than a conventional compressed tablet. This structure permits a functional enteric coating around individual pellets.

Enteric-coating excipients

The most commercially important excipients are the polymers that control gastric resistance and intestinal release. Common options include:

• Methacrylic acid-ethyl acrylate copolymers
• Methacrylic acid-methyl methacrylate copolymers
• Cellulose acetate phthalate
• Hypromellose phthalate
• Hypromellose acetate succinate

Plasticizers such as triethyl citrate, polyethylene glycol, or propylene glycol improve film flexibility. Talc can reduce tack during coating. Polysorbate 80 or related surfactants can improve coating uniformity.

The polymer selection controls dissolution behavior, coating weight, mechanical durability, and manufacturing cost. A formulation that releases too early risks gastric degradation. A coating that releases too late can reduce exposure and create food-effect or onset concerns.

Protective subcoats

A subcoat can separate the acidic drug-containing layer from the enteric polymer. Subcoats commonly use hypromellose, povidone, or other film-forming materials. They can improve chemical stability and reduce interaction between alkaline magnesium-containing drug particles and acidic enteric polymers.

For esomeprazole, the subcoat is a potential intellectual-property and performance-control point. It can affect stability, dissolution, coating adhesion, and scale-up reproducibility.

How should an excipient strategy be designed for Equate esomeprazole magnesium?

The optimal strategy is a cost-controlled enteric system that meets dissolution and stability requirements without creating unnecessary formulation complexity.

1. Protect the acid-labile active ingredient

Esomeprazole magnesium requires a high-performing enteric barrier. The primary development targets are:

• Acid resistance during simulated gastric exposure
• Rapid release at intestinal pH
• Low degradation during accelerated stability testing
• Consistent drug distribution across the dosage unit
• Resistance to moisture ingress

The formulation should minimize residual water and control exposure to acidic excipients. Hygroscopic materials, acidic colorants, and moisture-permeable packaging can increase degradation risk.

2. Select a scalable dosage form

A compressed delayed-release tablet may provide lower unit cost, simpler packaging, and higher line throughput. A multiparticulate capsule can offer more uniform coating and lower risk from localized coating defects, but it normally requires additional pelletization, capsule-filling, and inspection steps.

Dosage form	Cost profile	Technical profile	Commercial use
Enteric-coated tablet	Lower to moderate	Efficient, compact, scalable	Value OTC products
Enteric-coated capsule with pellets	Moderate to high	Strong release control and dose uniformity	Premium or differentiated products
Orally disintegrating formulation	Moderate to high	Requires taste and moisture control	Swallowability positioning
Sprinkle capsule	High	Supports administration flexibility	Pediatric or special-use opportunity
Chewable tablet	Moderate	Requires acid protection and taste masking	Limited opportunity because of PPI stability

The tablet platform is usually the most attractive for a mass-market Equate product. Multiparticulate technology becomes more valuable when the objective is a premium line extension rather than the lowest possible cost.

3. Control coating weight and process variability

Enteric coating is a major source of manufacturing risk. Key process variables include:

• Polymer solids concentration
• Spray rate
• Inlet and product temperature
• Atomization pressure
• Pan or fluid-bed airflow
• Coating weight gain
• Drying endpoint
• Film plasticization

A small reduction in coating weight may cause gastric release failure. Excess coating can delay intestinal release and increase material cost. A robust design should establish a wide operating window before commercial scale-up.

4. Use excipients with reliable supply

Equate is a high-volume private-label product. Supplier qualification is therefore commercially important. The formulation should avoid dependence on a single specialty polymer, proprietary coating system, or excipient supplier unless that material produces a material performance advantage.

Priority should be given to:

• Multiple qualified sources
• Compendial-grade materials
• Stable regional supply
• Low minimum-order quantities
• Established regulatory documentation
• Consistent particle-size and viscosity specifications

Excipient substitution can trigger comparability work, dissolution studies, stability studies, and regulatory updates. A low-cost excipient is not commercially attractive if it creates repeated post-approval change costs.

What regulatory requirements apply to Equate esomeprazole magnesium?

OTC esomeprazole products are regulated under the FDA proton pump inhibitor framework and applicable OTC labeling requirements. The product must meet requirements for active ingredient identity, strength, dosage form, labeling, quality, and performance.

The most important quality attributes are:

• Assay and content uniformity
• Related substances and degradation products
• Acid-stage dissolution
• Buffer-stage dissolution
• Water content
• Microbial quality
• Tablet or capsule integrity
• Stability through labeled shelf life

The delayed-release function is central to regulatory acceptance. Excipient changes that alter dissolution or stability may require regulatory reporting and supporting data under FDA post-approval change requirements.

What is the FDA regulatory status?

Esomeprazole magnesium is an established FDA-approved active ingredient with extensive generic and OTC use. Equate is a private-label retail brand rather than a distinct innovator molecule. Walmart products are generally supplied by a third-party manufacturer or private-label pharmaceutical partner, and the responsible manufacturer may vary by product and time.

The relevant regulatory documents are the current product label, Drug Facts panel, NDC listing, DailyMed entry where available, and FDA Orange Book information for the underlying approved product. FDA’s OTC monograph system and approved applications provide the regulatory framework for products in this category (FDA, 2024a; FDA, 2024b).

What patents protect esomeprazole magnesium and Equate esomeprazole?

The core esomeprazole patent estate is no longer a meaningful barrier to routine generic or private-label entry.

AstraZeneca’s original esomeprazole patents covered the active enantiomer, salts, formulations, and therapeutic uses. Key early patents included U.S. Patent No. 5,714,504, which covered esomeprazole-related subject matter and expired after the statutory patent term, subject to applicable patent-term adjustment or extension. The major commercial protection period ended years before Equate’s current OTC positioning.

IP category	Current commercial effect
Core esomeprazole compound	Expired or commercially exhausted
Magnesium salt protection	No meaningful barrier to standard entry
Original delayed-release technology	Largely expired or circumventable
Method-of-use patents	Limited relevance to labeled OTC use
Formulation patents	Potentially relevant only if tied to a specific supplier formulation
Trade secrets	Coating process, scale-up parameters, and supplier know-how remain relevant
Patent litigation risk	Low for standard 20 mg OTC entry

Are there Paragraph IV challenges?

Paragraph IV litigation was historically important for generic esomeprazole products, particularly when branded Nexium patents were still active. For a current Equate-style OTC product, Paragraph IV risk is generally lower because the foundational patents have expired and numerous generic manufacturers have entered the market.

A supplier may still face patent issues if it adopts a newly patented formulation, delivery system, manufacturing process, or combination product. Standard delayed-release esomeprazole magnesium does not present the same litigation profile as a recently launched protected product.

Are biosimilars a risk?

No. Esomeprazole magnesium is a small-molecule drug. Competitors enter through generic or abbreviated approval pathways, not through the biosimilar pathway. The relevant competitive risks are ANDA approvals, OTC monograph compliance, private-label substitution, authorized generics, and retailer sourcing decisions.

What formulation patents could create commercial opportunities?

The strongest formulation opportunities involve improved administration, stability, or adherence rather than basic acid suppression.

Potentially valuable patentable areas

• Low-dose or high-load enteric tablets
• Reduced-size tablets for easier swallowing
• Multiparticulate capsules with improved dissolution consistency
• Moisture-resistant packaging and dosage forms
• Taste-masked orally disintegrating products
• Sprinkle formulations
• Dual-release or extended-release systems
• Combination products with antacids or alginates
• Formulations designed for reduced food-effect variability
• Manufacturing processes that reduce coating defects
• Improved stability under high-temperature and high-humidity conditions

Patent value will depend on claim breadth and freedom to operate. A narrow patent covering a specific polymer ratio or coating process may protect a supplier’s formulation but have limited value if competing products can use alternative polymers.

How strong is the patent estate for Equate esomeprazole magnesium?

The patent estate is weak as a barrier to basic market entry but potentially meaningful as a defensive asset around manufacturing and differentiated delivery.

Patent-strength factor	Assessment
Core molecule	Weak; established and off-patent
Standard 20 mg delayed release	Weak to moderate
Enteric coating composition	Moderate if claims are narrow and performance-linked
Manufacturing process	Moderate where scale-up know-how is difficult to replicate
New delivery format	Potentially strong if clinically or commercially differentiated
Supplier trade secrets	Strong operational value, limited public enforceability
Retailer exclusivity	Commercially important but not patent protection

The practical moat is operational: approved manufacturing capacity, coating performance, quality systems, supply reliability, and retailer access.

What commercial opportunities exist for Equate esomeprazole magnesium?

Private-label price segmentation

The most immediate opportunity is tiered private-label pricing:

1. Standard 20 mg delayed-release tablets or capsules
2. Larger-count value packages
3. Premium smaller-count travel packages
4. Combination heartburn products
5. Formulations optimized for swallowing or administration flexibility

Because the active ingredient is off-patent, unit economics depend on manufacturing yield, packaging, retailer margin, and inventory turns.

Packaging and adherence

A 14-day OTC course creates opportunities for calendarized blister packs, clear day-by-day labeling, and tamper-evident packaging. These changes may not create strong patent protection, but they can improve shelf differentiation and reduce medication errors.

Unit-dose blister packaging increases packaging cost but may support premium pricing and improve consumer adherence. Bottles remain more economical for high-volume value products.

Combination products

Potential combinations include esomeprazole with antacids or alginate-based reflux barriers. These products face greater formulation and regulatory complexity because each active ingredient must remain stable and bioavailable. They can also create new freedom-to-operate issues around dosing sequence, release profiles, and packaging.

International expansion

Geographic opportunities exist in markets where:

• OTC proton pump inhibitor access is permitted
• Private-label pharmacy distribution is underdeveloped
• Local production costs are favorable
• Esomeprazole has established consumer recognition
• Local packaging and language requirements can be met efficiently

Patent risk is jurisdiction-specific, but core molecule protection has generally expired in major markets. Local regulatory classification, trademarks, data requirements, and manufacturing authorization remain important.

How does Equate compare with Nexium 24HR and generic esomeprazole?

Factor	Equate	Nexium 24HR	Generic pharmacy product
Brand position	Value private label	Branded OTC	Low-cost pharmacy generic
Active ingredient	Esomeprazole magnesium	Esomeprazole magnesium	Esomeprazole magnesium
Typical strength	20 mg	20 mg	20 mg
Patent advantage	None material	Historical brand protection	None material
Consumer advantage	Price and Walmart access	Brand recognition and marketing	Pharmacy availability
Excipient differentiation	Usually limited	May include proprietary or brand-specific formulation choices	Supplier-specific
Main commercial risk	Retailer margin and supplier continuity	Brand erosion	Price competition
Regulatory risk	Label and quality compliance	Brand-specific OTC compliance	ANDA or OTC compliance

The clinical differentiation among standard 20 mg delayed-release products is likely limited when products meet applicable quality and dissolution requirements. Commercial differentiation therefore depends on price, package count, availability, and consumer trust.

What generic launch risks exist?

The main risks are manufacturing and channel risks, not molecule-level patent risk.

• Enteric-coating failures can cause dissolution nonconformance.
• Moisture exposure can reduce shelf life.
• Excipient supply interruptions can delay production.
• Supplier changes can require comparability work.
• Retailer inventory policies can pressure margins.
• Product recalls can damage the private-label relationship.
• New combination or delivery products can create patent exposure.
• Aggressive generic pricing can compress contribution margins.

A dual-source strategy for critical excipients and qualified backup manufacturing capacity can reduce supply risk. The formulation should be designed around interchangeable, commercially available polymers and standard film-coating equipment where possible.

What is the revenue exposure for Equate esomeprazole?

Exact Equate revenue is not publicly separated in Walmart’s reporting. The relevant exposure is the retailer’s private-label share of the U.S. OTC heartburn market, rather than a separately reported product franchise.

Revenue sensitivity is driven by:

• Package count
• Retail price
• Walmart store and online distribution
• Promotion frequency
• Generic and branded competitor pricing
• Product availability
• Contract manufacturing cost
• Consumer switching from branded Nexium

The product is likely to have modest revenue per unit but high volume potential. Manufacturing yield and retailer economics are more important than patent royalties because the active ingredient is off-patent.

Key Takeaways

• Equate esomeprazole magnesium competes primarily through price, distribution, and package economics.
• The central formulation challenge is protecting acid-labile esomeprazole until intestinal release.
• Enteric polymers, subcoats, plasticizers, moisture control, and coating processes determine product performance.
• The core esomeprazole patent estate no longer presents a material barrier to standard generic or private-label entry.
• Paragraph IV risk is low for conventional 20 mg delayed-release products but can reappear with patented delivery systems or combination products.
• No biosimilar pathway applies because esomeprazole is a small molecule.
• The strongest commercial opportunities are premium delivery formats, combination heartburn products, packaging differentiation, and international private-label expansion.
• The practical competitive moat is manufacturing reliability, quality compliance, supplier redundancy, and retailer access.

FAQs

Can Equate esomeprazole use the same excipients as Nexium 24HR?

Yes, a private-label product can use similar excipients, but it does not need to duplicate the branded formulation. It must meet applicable quality, stability, labeling, and delayed-release performance requirements.

Is esomeprazole magnesium more difficult to formulate than omeprazole?

The two drugs share acid-lability and require gastric protection. Esomeprazole formulations can still present challenges involving salt form, particle properties, stability, coating uniformity, and dissolution control.

Can a new enteric coating create patent protection for an Equate product?

Potentially, but only if the coating composition or process satisfies patentability requirements and the claims are sufficiently broad and enforceable. A routine substitution of known enteric polymers is unlikely to create strong protection.

What is the best dosage form for a low-cost private-label product?

A delayed-release tablet is generally the strongest low-cost option because it can support high-throughput manufacture and economical packaging. A pellet-filled capsule may provide better formulation flexibility but usually costs more.

Does an excipient change require FDA approval?

The regulatory impact depends on the change, its effect on quality and performance, and the applicable approval pathway. Changes affecting dissolution, stability, identity, strength, or dosage-form performance require documented evaluation and may require regulatory reporting or prior approval.

References

1. U.S. Food and Drug Administration. (2024a). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/

2. U.S. Food and Drug Administration. (2024b). DailyMed and FDA labeling resources. https://dailymed.nlm.nih.gov/

3. U.S. Food and Drug Administration. (2024c). Code of Federal Regulations, Title 21, Part 216: OTC drugs. https://www.ecfr.gov/

4. AstraZeneca. (2001). Nexium esomeprazole magnesium prescribing information. U.S. Food and Drug Administration labeling archive.

5. U.S. Patent No. 5,714,504. (1998). Pyridine derivatives for use in the treatment of gastric acid-related diseases. U.S. Patent and Trademark Office.